Clinical Trial Update: Use of Novel Prebiotic Fiber for Targeted Dietary Management of Irritable Bowel Syndrome (Nutrabiotix Phase II) [Phase 2]

View source ↗

Summary

Nutrabiotix's Phase II trial evaluating a novel prebiotic fiber for constipation-predominant irritable bowel syndrome (IBS-C) has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Irritable Bowel Syndrome

Drugs mentioned

• Novel Prebiotic Fiber

Snippet

Sponsor: Nutrabiotix, LLC | Conditions: Constipation-predominant IBS (IBS-C) | Phase 2 | Status: TERMINATED